Compare UnitedHealth Group Inc (UNH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UnitedHealth Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? UnitedHealth Group Inc trades at $379.3 (market cap $332.96B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: UnitedHealth Group Inc is far larger — about 32.9× State Street SPDR S&P Biotech ETF's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold UnitedHealth Group Inc for 97 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UNH | XBI | |
|---|---|---|
Market Cap | $332.96B | $10.11B |
Volume | 7,273,749 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $436.35 | $169.55 |
52-Week Low | $259.02 | $104.99 |
Typical Hold Time | 97 Days | 38 Days |
Enterprise Value | $374.82B | — |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.
UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
